Citation:Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, et al 2011

From Cancer Guidelines Wiki

Citation


Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 2011 Jan 20;6(1):e15980 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21283802.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Optimal molecular profilingDr Albert Chetcuti BTech(Biotech) Hons, PhDcompleted
Optimal molecular profilingBen Lee-Batescompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:Molecular profiling of CRC|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Molecular profiling of CRC</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Molecular profiling of CRC|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Molecular profiling of CRC</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Optimal molecular profiling